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Ultraviolet radiation (280^400 nm)-induced suppression
of cutaneous cell-mediated immunity plays an impor-
tant part in the development of skin cancer. Sunscreens
are widely advocated to protect against skin cancer but
if they o¡er insu⁄cient protection against immunosup-
pression they may inadvertently increase skin cancer
risk.This human study evaluated immunoprotection af-
forded by a commercial sunscreen preparation (labeled
sun protection factor 15) o¡ering primarily ultraviolet
B (280^320 nm) protection. Indirectly, it also investi-
gated whether ultraviolet A (320^400 nm) plays a part
in ultraviolet radiation-induced immunosuppression.
Healthy white-skinned volunteers were used (n¼119).
Ultraviolet radiation exposures were on previously un-
exposed buttock skin with an ultraviolet radiation
source that complied with European recommendations
for sunscreen testing. Ultraviolet radiation dose^re-
sponse curves for sunburn/erythema and suppression of
the contact hypersensitivity response were generated
either with or without sunscreen in vivo and protection
factors were derived for both end-points. The ultravio-
let radiation wavelengths transmitted by the sunscreen
were determined in vitro and showed that the sunscreen
was primarily an ultraviolet B absorber, with relatively
poor absorption in the ultraviolet A region. The sun-
screen protected against both erythema and immuno-
suppression but protection against immunosuppression
(IPF= 4.9, 95% con¢dence interval: 2.3^10.6) was less
than half that for erythema (Ery-PFg= 14.2, 95% con¢-
dence interval: 10.2^19.8). Failure of the sunscreen to af-
ford comparable protection against both end-points was
probably due to immunosuppression by ultraviolet A, a
part of the solar spectrum that does not readily cause
sunburn. The sunscreen protected against both end-
points, which supports the use of sunscreens to reduce
immunosuppression but protection against immuno-
suppression may be improved if sunscreens are formu-
lated to o¡er equivalent protection against ultraviolet B
and ultraviolet A. Key words: contact hypersensitivity/
immunosuppression/sunscreen/ultraviolet A. J Invest Derma-
tol 120:000 ^000, 2003
I
t is well established that exposure to ultraviolet radiation
(UVR; 280^400 nm) suppresses cutaneous cell-mediated
immunity in both humans and animal models. UVR-in-
duced immunosuppression plays an important part in the
emergence and growth of nonmelanoma skin cancers in
mice (Nishigori et al, 1996). A similar role is suspected in humans
as transplant patients maintained on immunosuppressive therapy
have an elevated risk of both nonmelanoma and melanoma skin
cancers, especially if they have a history of high sun exposure
(Euvrard et al, 1997).
Sunscreens are designed to protect against sunburn/erythema,
as indicated by their sun protection factor (SPF), but are widely
advocated to reduce skin cancer risk; however, the relationship
between SPF and protection against other end-points important
in the development of skin cancer, in particular immunosuppres-
sion, has not been established. Exposure to UVR also increases
the incidence and/or severity of infectious diseases in animal
models (Jeevan et al, 1995) and suppresses the elicitation of immu-
nity to some infectious agents in humans (Cestari et al, 1995;
Moyal et al, 1997) and therefore has implications for susceptibility
to infectious diseases and vaccine e¡ectiveness in humans. Thus
there appears to be a need for immunoprotective sunscreens.
UVR-induced suppression of cell-mediated immunity can be
evaluated in vivo by measuring the impairment of a contact hy-
persensitivity response (CHS) to chemical haptens. This end-
point has been widely used to compare sunscreen protection
against erythema and immunosuppression. The majority of these
studies suggest that sunscreen protection against immunosuppres-
sion is lower than that for erythema. This has raised doubts about
the bene¢ts of sunscreen use in the prevention of skin cancer. In
many cases, however, the discrepancies between protection from
erythema and immunosuppression can be attributed to defects in
experimental design (for reviews see Roberts and Learn, 1997;
Young andWalker, 1999). For example, very few studies have as-
sessed immunoprotection with experimental conditions compar-
able with those recommended for SPF testing. Sunscreen SPF is,
by de¢nition, estimated using solar-simulated radiation (SSR)
and a de¢ned sunscreen application density (2 mg per cm2). Only
nine studies, however, have used SSR and the correct sunscreen
application density to determine immunoprotection (Fisher et al,
1989; Ho et al, 1992; Bestak et al, 1995; Roberts and Beasley, 1995,
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1997; Damian et al, 1997; Moyal et al, 1997; Serre et al, 1997; Four-
tanier et al, 2000). Even when SSR is used, the majority of these
studies used multiple SSR exposures to test immunoprotection
(Bestak et al, 1995; Fisher et al, 1989; Ho et al, 1992;Damian et al,
1997; Moyal et al, 1997) despite the fact that a sunscreen’s SPF rat-
ing is a measure of protection from erythema after a single SSR
exposure. It is likely that chronic exposure will lower sunscreen
immune protection factor (IPF) as it is reported that events that
initiate immunosuppression, such as DNA damage (Sheehan et al,
2002) and cis-urocanic acid (Krein and Moyal, 1994), and damage
to immune end-points (Noonan et al, 1981; Murphy et al, 1993)
accumulate with multiple UVR exposures.
It is also important to realize that SPF is a ratio calculated from
a very simple formula, i.e.,
SPF ¼
Minimal Erythema Dose ðMEDÞ with sunscreen
MED without sunscreen
The MED is the threshold dose in a dose^response. Therefore,
in order to understand fully the relationship between SPF and
IPF it is essential that UVR dose^response studies, both with
and without the sunscreen, are performed. We have recently
shown that the UVR dose threshold for immunosuppression in
sun-sensitive humans, skin types I/II, is much lower than that for
erythema. A single exposure of 0.25 MED or 0.5 MED sup-
pressed CHS by 50% and 80%, respectively (Kelly et al, 2000).
Therefore, even if a sunscreen o¡ers the same protection against
both erythema and immunosuppression (i.e., SPF¼ IPF) it is still
possible to protect completely against erythema but induce sub-
stantial immunosuppression. Commercial sunscreens have been
shown to o¡er complete protection against SSR-induced erythe-
ma and suppression of CHS in human skin (skin types II/III)
with a SPF-15 sunscreen and a single exposure to 3 MED (Serre
et al, 1997). The daily dose transmitted through the sunscreen (0.2
MED), however, was probably too small to induce signi¢cant
immunosuppression. The same sunscreen may have failed to af-
ford complete protection in skin types I/II if a higher SSR dose
was used to test the sunscreen. For example, a SPF-15 sunscreen
would transmit 0.5 MED if tested with a dose of 8 MED.
Protection against erythema (SPF) is primarily a measure of
protection against solar UVB (E295^320 nm) because the UVB
content of solar UVR is responsible for about 80% of a sunburn
response. Therefore, unless a sunscreen attenuates all wavelengths
equally it may a¡ord limited protection against UVA (320^400
nm) exposure. The ability of UVA to suppress CHS is unclear.
A wavelength dependency study for the suppression of CHS in
the mouse indicated that immunosuppression was more readily
induced by UVA than erythema (De Fabo and Noonan, 1983),
but this was not con¢rmed in another study (Elmets et al, 1985).
Other studies indicate that a single low dose of UVA can reverse
the immunosuppressive e¡ects of prior UVB exposure in
the mouse (Reeve et al, 1998). In this case, use of a sunscreen that
primarily absorbed UVB but transmitted UVAwould give great-
er protection against UVR-induced immunosuppression than
erythema. Only three studies, all using mouse models, have
determined IPF using methods recommended for SPF testing
(Roberts and Beasley, 1995, 1997; Fourtanier et al, 2000). Two
studies that used sunscreens that were primarily UVB absorbers
found that the IPF was at least 2-fold greater than the labeled
SPF (Roberts and Beasley, 1995, 1997). In contrast, we have re-
cently shown that two sunscreen preparations with the same
SPF but di¡erent levels of UVA protection a¡orded di¡erential
protection against immunosuppression in mice. Our data sug-
gested that UVAwas immunosuppressive (Fourtanier et al, 2000).
As yet, no comparable studies have been done in humans.
The aim of this study was to determine if a high SPF sunscreen
(labeled SPF 15) could o¡er comparable protection against er-
ythema and immunosuppression in humans, using methods re-
commended for SPF testing.We chose a sunscreen that absorbed
primarily in the UVB region to investigate indirectly the role of
UVA on cutaneous immune suppression.
MATERIALS ANDMETHODS
Volunteers One hundred and twenty-eight white-skinned Caucasian
volunteers (18^35 y), were recruited from sta¡ and students at Guy’s,
King’s, and St Thomas’ Hospitals, London, U.K. The study was approved
by St Thomas’ Hospital ethics committee and volunteers gave written,
informed consent to participate. Exclusion criteria included ill health, a
history of skin cancer or cutaneous photosensitivity disorders, medication
(oral contraceptive pill excepted), previous exposure of buttock skin (test
site) to sunlamps or sunlight, a recent sunburn, a history of atopy,
anaphylaxis, previous exposure to the contact allergen 2,4-dinitro-
chlorobenzene, and a history of allergy to sunscreens. Pregnant or lactating
females were also excluded as were outdoor workers and people who
participated in regular outdoor sport.
Skin type was assessed by interview and erythema assessment. One
hundred and nineteen volunteers completed the study; 116 were skin type
I/II (sun sensitive/tan poorly; 85 females and 31males). The remaining three
were skin type III (sun tolerant/tan well; one female and two males). The
nine volunteers who failed to complete the study either did not complete
all the treatment sessions or were excluded because they took over-the-
counter medication.
The volunteers who completed the study were randomly assigned to
di¡erent treatment groups as follows: (i) 26 volunteers (nine skin type I, 14
skin type II, and three skin type III) were used to determine the SPF with
21 of these volunteers also used to determine an individual erythema
protection factor (Ery-Pfi); (ii) 83 skin type I/II volunteers were used for
determination of the relationship between sunscreen protection UVR-
induced erythema and immunosuppression (42 of which were used in the
sunscreen-treated groups and 41 in the nonsunscreen-treated groups); and
(iii) 10 volunteers were used as sunscreen controls to determine the
nonspeci¢c irritant e¡ects of hapten challenge (see Sensitization).
UVR source and dosimetry SSRwas generated by a 1 kW xenon arc
solar simulator (Oriel Corporation, Stratford, CT) giving an even ¢eld of
irradiance (297^400 nm) of about 15 mWper cm2 on the skin surface at 11
cm from the source. AWG320/1 mm thick glass ¢lter was used, through
which the emission spectra conformed to the European Cosmetic Toiletry
and Perfumery Association (COLIPA) recommendations (COLIPA, 1994).
Irradiance was routinely determined with a wide-band thermopile
radiometer (Medical Physics, Dryburn Hospital, Durham, U.K.) calibrated
against a DM150 double monochromator Bentham spectroradiometer
(Bentham Instruments, Ltd, Reading, U.K.). Eighty-eight per cent of the
erythemally e¡ective energy of the source was in the UVB range with the
remaining 12% in the UVA.
Sunscreen The sunscreen, formulated in the U.S.A. (Neutrogena Corp.
Los Angeles, CA), was a commercial waterproof formulation with a
labeled SPF of 15 and claimed to o¡er broad-spectrum UVB/UVA
protection. The active ingredients were 7.5% octyl methoxycinnamate, a
UVB absorber and 3% benzophenone-3, a UVA absorber and are used in
commercial sunscreen formulations world-wide. It also contained vitamin
A and E as anti-oxidants (concentrations unspeci¢ed).
The UVR transmission spectra (T) of the sunscreen preparation was
determined in vitro (Di¡ey and Robson, 1989). The UVR transmitted
through Transpores tape, with and without the sunscreen applied at 2 mg
per cm2, was measured spectroradiometrically and the monochromatic
protection factors (mPF) were calculated (mPF¼1/T) (Fig 1).
SPF and individual erythema protection factor (Ery-PFi) The SPF
of the sunscreen was determined in vivo (n¼ 26), according to COLIPA
(1994) recommendations. Brie£y, the minimal dose of SSR required to
induce a just visibly perceptible erythema at 24 h (MED) was determined
on the buttock skin of each volunteer, with and without sunscreen using a
geometric series of eight exposure doses with increments of 1.25. SPF was
determined in a group of volunteers before (n¼10), during (n¼ 7), and
after (n¼ 9) the immunoprotection study.
The SPF was determined for each individual as follows:
SPF¼MED with sunscreen/MED without sunscreen
Erythema intensity on the ‘‘UVR only’’ and the ‘‘UVRþ sunscreen-
treated’’ sites was also quanti¢ed in triplicate for 21 of the 26 volunteers
using a re£ectance meter (Diastron, Andover, U.K.). For each volunteer
the increase in erythema (erythema index) was calculated by subtracting
the mean background reading from adjacent nonirradiated skin. These
data on erythema intensity (18 measurement sites per subject), were used
to determine an erythema protection factor for each individual (Ery-PFi)
(see Statistical methods).
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Determination of the relationship between sunscreen protection
against UVR-induced erythema and immunosuppression Volunteers
were randomly assigned to one of two groups, a ‘‘UVRþ sunscreen group’’
(n¼ 42) and a ‘‘UVR only group’’ (n¼ 41). The MED was determined for
each volunteer, as previously described. We made the assumption that the
SPF of the sunscreen was 10, based on our ¢rst SPF determination. Therefore,
groups of individuals (n¼ 6^8) were irradiated with a single SSRexposure on
a 55 cm site on the right buttock of either 0, 0.2, 0.4, 0.6, 0.8, or 1 MED
without the sunscreen, or 0, 2, 4, 6, 8, or 10 MED with sunscreen. Sunscreen
application complied with COLIPA (1994) guidelines.Twenty-four hours after
UVR exposure, quantitative measurements of erythema intensity on the
irradiated site, were made as previously described. Dose^response curves for
UVR-induced erythema, with or without sunscreen, were obtained by
plotting each individual’s erythema response vs physical UVR dose (J per
cm2) (Fig 2a,b). These data from the sunscreen-treated groups and
nonsunscreen groups were used to determine an erythema protection factor
(Ery-PFg) (see Statistical methods).
Sensitization Volunteers were sensitized on buttock skin with 2,4-
dinitrochlorobenzene (DNCB; Sigma-Aldrich Company Ltd, Dorset,
U.K.), 24 h after irradiation. This was via the irradiated site using a
petrolatum-backed 12 mm ¢lter disk, soaked in 50 ml of 0.0625% of
DNCB in ethanol (31.2 mg per 50 ml). The ¢lter paper disc was mounted
inside a 12 mm aluminum Finn chamber (Biodiagnostics Ltd, Silchester,
Reading, U.K.) and taped in the center of the irradiated site for 48 h.
Two sunscreen control groups were treated with sunscreen and
sensitized with ethanol only (in the center of the sunscreen-treated site) to
determine the nonspeci¢c irritant e¡ects of DNCB challenge. Sunscreen-
treated sites were either unirradiated (n¼ 5) or received a single 10 MED
UVR exposure (n¼ 5) 24 h prior to application of ethanol.
Elicitation of CHS response Three weeks after sensitization,
volunteers were challenged on the UVR protected upper inner arm.
Eight millimeter ¢lter paper discs were placed in 8 mm Finn chambers
and soaked with 20 ml of hapten solutions of various strengths. Five
patches were placed on the test site; one was soaked in ethanol only and
four were soaked in incremental doses of DNCB (3.125, 6.25, 12.5, and
25.0 mg per 20 ml). The elicitation sites were mapped on the arm with a
surgical skin marker. The patch was taped in place for 48 h. At 72 h after
challenge, elicitation sites were quanti¢ed as outlined below.
Quanti¢cation of CHS responses The dermal thickness of each
elicitation site was determined using a high-frequency 20 MHz
ultrasound scanner (Quality Medical Instruments Ltd, Silchester,
Reading, U.K.), as previously described (Kelly et al, 1998). Ultrasound
images of each elicitation site were recorded immediately before and 72 h
after challenge. The percentage increase in dermal thickness was then
determined as follows:
ðDermal thickness at 72 h dermal thickness at 0 hÞ
ðDermal thickness at 0 hÞ

100%
The percentage increase in dermal thickness for each elicitation site was
plotted vs DNCB challenge dose (x-axis), and the dose^response
relationship was determined using linear regression analysis. The CHS
response of a given individual is represented by the slope of the linear
regression line. The steeper the slope the stronger the response.
UVR dose^response curves for suppression of CHS, with or without
sunscreen, were obtained by plotting each individual’s CHS response vs
physical UVR dose (J per cm2) (Fig 3a,b). These data were used to
determine an IPF (see Statistical methods).
Statistical methods Data were ¢rst entered into Excel and preliminary
calculations carried out. All further analyses were carried out in the
statistical package Stata version 6.0 (Stata Corp, College Station, TX). All
results are presented as estimates with 95% con¢dence intervals (CI).
Signi¢cance at po0.05 is claimed when ‘‘no e¡ect’’ (di¡erence¼ 0 or
ratio¼1) is not in the interval.
Determination of protection factors for UVR-induced erythema
and suppression of CHS In addition to the visually determined SPF
assessment, protection factors for erythema were also obtained from the
quantitative erythema data measured with the re£ectance meter. These
were (i) the individual erythema protection factor (Ery-PFi), calculated
using data from the SPF assessments where each individual was exposed
to a series of UVR doses with and without sunscreen, and (ii) the group
erythema protection factor (Ery-PFg), which was calculated using data
from the immunoprotection study where groups of individuals were
exposed to a single UVR dose with or without a sunscreen.
The IPF was calculated in a similar fashion to the Ery-PFg where groups
of individuals were exposed to a single UVR dose with or without a
sunscreen.
F-tests, diagnostic plots, and Cook’s distance were used to check the
assumptions of the regression models used to determine each protection
factor. In addition, the ratio of IPF/Ery-PFg was determined with a 95%
CI and p-value. This was based on a bootstrap procedure with percentage-
based CI after 10,000 replications.
Determination of erythema protection factor by two methods
(mean Ery-PFi and Ery-PFg) Two data sets were available to estimate
the erythema protection factor of the sunscreen. For the limited UVR
exposures used here, up to 1 MED, a nonlinear relationship was not
Figure1. The sunscreen a¡orded good UVB protection but limited
UVA-2 protection and virtually no protection in the UVA-1 region.
The UVR transmission spectrum (T) of the sunscreen was determined ac-
cording to the Di¡ey method (Di¡ey and Robson, 1989). Sunscreen was
applied to transpore tape at 2mg per cm2. The UVR transmitted at each
wavelength (T) was measured spectroradiometrically and the monochro-
matic protection factors (mPF) were calculated (mPF¼1/T).
Figure 2. (a,b) UVR dose^response curves for erythema. Exposure to
UVR induced a dose-dependent increase in erythema in both the ‘‘UVR
only’’ (a; D) and ‘‘UVR+sunscreen’’groups (b;~). Note;There are six data
points at (0,0) in a and b. The sunscreen’s erythema protection factor (Ery-
PFg) was 14.2 (95% CI: 10.2^19.8).
Figure 3. (a,b) UVR dose^response curves for suppression of CHS.
Exposure to UVR induced a dose-dependent suppression of CHS in both
the ‘‘UVR only’’ (a; J) and ‘‘UVR+ sunscreen’’ groups (b; ). The sun-
screen’s immunoprotection factor (IPF) was 4.9 (95% CI: 2.3^10.6).
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needed. In both cases, we assumed a linear relationship between erythema
and UVR exposure, adjusted as necessary for protection:
mEI ¼ E½EI	 ¼ aþ b nUVRdose=Ery-PF ð1Þ
Here EI is the erythema index for a given UVR dose expressed in J per
cm2. mEI is the expected value of EI. Ery-PF was ¢xed at 1 for
unprotected skin and was a parameter to be estimated for skin protected
with sunscreen. Two possible sources of variation were allowed for:
di¡erences in individual erythema protection factors (Ery-PFi) between
subjects and measurement error in determining the EI.
Di¡erent methods of analysis were needed for the di¡erent data sets.
Individual erythema protection factors (mean Ery-PFi) The Ery-
PFi is determined from the same experiment as used to determine the
SPF. Eighteen observations were available on 21 volunteers. Separate Ery-
PFi values were determined for each volunteer by nonlinear regression
with normal errors (Gallant, 1987; Royston, 1992) using model (1) above.
As the distribution of the values was roughly log-normal, the geometric
mean of Ery-PFi is reported, with CI based on the log-normal distribution.
Erythema protection factor from grouped data (Ery-PFg) Erythema
data were obtained from the 83 subjects receiving CHS testing. A single
nonlinear regression was performed based on model (1) above. To improve
convergence and remove complications related to estimating impossible
values, Ery-PF was replaced with exp(LogE), where LogE¼ log (Ery-PFg).
The estimate and CI of LogE were anti-logged to give values for Ery-PFg.
UVR was expressed in J per cm2 and natural logs (base e) were used
throughout.
Determination of IPF The regression slope representing the change in
CHS response following a single UVR exposure was calculated for each
volunteer as previously reported (Kelly et al, 1998). Although this does not
model the full complexity of the response to DNCB challenge, it
accurately estimates its most important feature: the steadily increasing
elicitation response with greater DNCB challenge doses, and the way that
this is a¡ected by UVR dose (Matthews et al, 1990).
These calculated CHS responses were heavily skewed, with some
negative values at the higher UVR exposure doses where CHS was
completely suppressed. Because the residuals of the nonlinear regression,
should be normally distributed, a square root transformation was used. To
accommodate the negative values, the transformation was based on the
square root of the absolute value of the slope:
Y ¼ sign ðslopeÞ n sqrtðjslopejÞ
This power transformation does not alter the shape of the nonlinear
exponential curves, or the way the IPF is de¢ned, but does improve the
distribution of the residuals and the robustness of the CI.
A two-parameter exponential curve was then ¢tted using nonlinear
regression (Ratkowsky, 1983; Gallant, 1987; Royston, 1992) where:
mY ¼ E½Y	 ¼ b1 n b
ðX= expðf ÞÞ
2
Y is the CHS response, square-root transformed, as described above. mY is
the expected value of Y. X is the UVR dose (J per cm2). b1 is the value of
Y at X¼ 0, b140. b2 determines the rate of decrease of Y as X changes.
b240. The IPF¼ exp(f) and was ¢xed at 1 for unprotected skin.
RESULTS
The sunscreen absorbed primarily in the UVB region In
vitro assessment of the sunscreen preparation (Di¡ey and
Robson, 1989) showed that the product a¡orded good UVB
protection compared with UVA-2 (320^340 nm) protection, and
virtually no protection in the UVA-1 region (340^400 nm)
(Fig 1).
The sunscreen protected against erythema: the three
methods used to determine protection against erythema
gave comparative results The mean SPF determined visually
according to COLIPA (1994) guidelines (n¼ 26), was 11.1 (CI:
10.3^11.9). Sunscreen protection against erythema based on
quantitative erythema readings in 21 of these volunteers gave a
mean Ery-PFi of 13.4 (CI: 11.0^16.2).
Exposure to UVR induced a dose-dependent increase in
erythema intensity in both the ‘‘UVR only’’ (n¼ 41) and the
‘‘UVRþ sunscreen’’ group (n¼ 42) (Fig 2a and b, respectively).
The sunscreen protected against erythema because, for a given
UVR dose, erythema responses were lower in the ‘‘UVRþ
sunscreen’’ group than the ‘‘UVR only’’ group. The sunscreen’s
Ery-PFg was 14.2 (CI: 10.2^19.8). The goodness of ¢t for the
regression model was r2¼ 0.5027, po0.001 with no apparent
nonlinearity, heterskedasticity or non-normality.
Sunscreen application had no e¡ect on CHS responses in
unirradiated volunteers Sunscreen application prior to
DNCB sensitization had no e¡ect on subsequent elicitation
responses in unirradiated volunteers. There was no signi¢cant
di¡erence in the slope of the CHS elicitation response for
unirradiated volunteers sensitized via a sunscreen-treated site
(n¼ 6) (mean slope¼ 5.97, CI 3.55^10.02), vs unirradiated
volunteers sensitized via untreated skin (n¼ 6) (mean slope 4.46,
CI 3.13^6.34) p¼ 0.3. A power calculation estimates that data
from 100 subjects would be needed (50 in each group) to have
90% power to detect a di¡erence of this size at the 5%
signi¢cance level.
Sunscreen application did not induce nonspeci¢c irritation in
unirradiated volunteers or volunteers irradiated with 10 MED.
Volunteers sensitized with ethanol via sunscreen-treated skin
(n¼ 5) or via sunscreen-treated skinþ10 MED (n¼ 5) and
challenged as normal with DNCB, failed to elicit a CHS
response. Analysis of ultrasound images taken before and after
challenge showed a negligible change in dermal thickness at all
DNCB doses. The greatest slope recorded in either group was
0.04, a value about 100-fold lower than that of sensitized
controls shown above.
The sunscreen protected against UVR-induced suppression
of CHS but immunoprotection was 50% lower than
protection against erythema Exposure to UVR induced
a dose-dependent suppression of CHS responses in both
the ‘‘UVR only’’ and the ‘‘UVRþ sunscreen’’ groups (Fig 3a
and 3b, respectively). The sunscreen protected against
immunosuppression because, for a given UVR dose, CHS
responses were higher in the ‘‘UVRþ sunscreen’’ group than the
‘‘UVR only’’ group. The sunscreen’s IPF, determined using a
similar approach as the Ery-PFg, was 4.9 (CI: 2.3^10.6). The
goodness of ¢t for the regression model was r2¼ 0.6735,
po0.001 with no apparent nonlinearity, heterskedasticity, or
non-normality.
The IPF was signi¢cantly lower than the Ery-PFg . IPF/Ery-
PFg¼ 0.36 (CI: 0.12^0.81) two-sided p-value: p¼ 2n0.0144¼ 0.03.
DISCUSSION
Sunscreens are widely advocated as a means of reducing skin can-
cer risk.This advice is largely based on extrapolation from animal
studies, as it is very di⁄cult to evaluate long-term protection in
humans. Limited data indicate that sunscreens can inhibit actinic
keratoses that are regarded as precursors of squamous cell carcino-
ma (Thompson et al, 1993; Naylor et al, 1995). A recent study in
Australia has also shown that daily use of a SPF 16 sunscreen, over
a period of 4.5 y, reduced the total number of squamous cell car-
cinoma by 40% but not the number of people with this tumor.
No protective e¡ect was seen for basal cell carcinoma (Green et al,
1999). Epidemiologic studies on the role of sunscreens in the pre-
vention of malignant melanoma show mixed results; some even
show that sunscreen use is associated with an increased risk of
melanoma (Weinstock, 1999; Young, 2002). The reasons for this
association are unclear. They may be due to behavioral factors;
for example, sun-sensitive people (skin types I/II) who are at
greatest risk of skin cancer are more likely to use sunscreens or
that sunscreens are used to prolong solar exposure (Autier et al,
1999). It has also been suggested that UVA may play a part in
the induction of melanoma (Moan et al, 1999) and that use of
sunscreens that o¡er poor protection against UVA may increase
melanoma risk by increasing UVA exposure (Garland et al, 1993).
4 KELLY ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
It is di⁄cult to distinguish between these possibilities using epi-
demiologic studies alone.
Another approach is to assess sunscreen protection against
short-term surrogates for skin cancer. Skin cancer is a multistep
process initiated by UVR-induced DNA lesions, such as cyclobu-
tane pyrimidine dimers. Occasional errors in DNA repair lead to
the generation of mutations, especially in the p53 tumor suppres-
sor gene, which have a direct role in the initiation of nonmelano-
ma skin cancer (Zeigler et al, 1994). In humans, more than 90% of
squamous cell carcinomas and 50% of basal cell carcinomas have
mutations in the p53 tumor suppressor gene and 75% of skin
cancer patients also have UVR-related p53 mutations in normal
sun-exposed skin (Nakazawa et al, 1994). Animal studies indicate
that immunosuppression plays an important part in allowing
these UVR-transformed cells to escape tumor surveillance me-
chanisms and develop into squamous cell carcinoma (Nishigori
et al, 1996). We lack a mouse model to study the role of UVR-
induced immunosuppression in the development of basal cell car-
cinoma or malignant melanoma, as these tumors do not occur in
mice with UVR alone, although some studies indicate that
UVR-induced immunosuppression accelerates the growth of
transplanted melanoma cells (Donawho and Kripke, 1991). At
present the data from organ transplant patients undergoing im-
munosuppressive therapy are the best indication that cutaneous
immunity is important in the development of all types of skin
cancer because the risk of squamous cell carcinoma, basal cell
carcinoma, and malignant melanoma, are all elevated in these
patients (Euvrard et al, 1997).
Failure of sunscreens to protect against UVR-induced DNA
lesions or immunosuppression may indicate a failure to protect
against skin cancer. The UVB component of sunlight is largely
responsible for the induction of dipyrimidine DNA lesions in
humans (Young et al, 1998), but the wavelength dependency for
the induction of immunosuppression has not been determined.
If UVA is immunosuppressive then sunscreens may inadvertently
increase skin cancer risk because they favor an environment that
favors the growth and emergence of UVB transformed cells.
We have previously shown that SPF predicts protection against
epidermal DNA photodamage and that this is independent of a
sunscreen’s UVA absorption pro¢le (Young et al, 2000). In other
words, the action spectra for erythema and DNA photodamage
are very similar, almost certainly because DNA is the major chro-
mophore for erythema (Young et al, 1998). At present we lack data
on the action spectrum for immunosuppression in humans but
animal data suggest that DNA is a candidate chromophore (Vink
and Rosa, 2001).
In this study, we tested the hypothesis that erythema and im-
munosuppression have a common action spectrum and therefore
a common chromophore. The use of a sunscreen to test this hy-
pothesis is an indirect approach and we predicted that if IPF ¼
SPF, after single SSR exposures, then erythema and immunosup-
pression share a common chromophore. This approach would
only work by using a sunscreen that o¡ered relatively poor
UVA protection as a true broad-spectrum formulation would
have attenuated all wavelengths equally and not provided any in-
formation on the relative wavelength dependency of erythema
and immunosuppression.
We therefore selected a commercial sunscreen preparation
(labeled SPF 15). This product contained UVB and UVA ¢lters
and was labeled ‘‘broad spectrum’’. It was found, however, to ab-
sorb primarily in the UVB region with some UVA-II absorption
but no UVA-I absorption, where nearly half the solar-UVA oc-
curs (Fig 1). AU.S.A. product was chosen as most European pro-
ducts have much better UVA protection.
Guidelines for sunscreen testing di¡er in the U.S.A. and
Europe and therefore, as SPF is highly dependent on the UVR
spectrum of the test source (Di¡ey and Robson, 1989), we
re-determined the SPF of the sunscreen according to European
(COLIPA, 1994) guidelines. SPF is a semiquantitative measure of
sunscreen protection against a visual threshold for sunburn/er-
ythema. Its relevance to protection at other levels of erythema is
not established.We therefore determined the sunscreen’s ability to
inhibit erythema by quantifying the erythema responses on the
same sites that were used to determine the SPF. The erythema
dose^response curves, with and without sunscreen, generated
from these measurements were used to calculate an Ery-PFi (13.4,
CI: 12.8^13.9). This value was comparable with the SPF (11.1, CI:
10.3^11.9) indicating that this was a valid model for assessing pro-
tection against erythema.
In order to investigate the relationship between sunscreen pro-
tection against erythema and immunosuppression we measured
the ability of UVR to suppress the induction phase of CHS. This
model shares many features in common with UVR-induced sup-
pression of tumor immunity (Noonan et al, 1981). Each volunteer
can only be sensitized once, and therefore UVR dose^response
studies are made using groups of volunteers exposed to di¡erent
UVRdoses.We quanti¢ed erythema responses on UVR-exposed
sites, with and without sunscreen, prior to sensitization.We have
termed this the group erythema protection factor (Ery-PFg).
The Ery-PFg is important because it is a measure of the degree
of protection on the actual CHS test site using the same statistical
techniques that were used to determine IPF; in other words a di-
rect comparison between the two end-points can be made. The
Ery-PFg was 14.2 (CI: 10.2^19.8) that was similar to the SPF and
Ery-PFi. Thus three di¡erent ways of assessing protection from
erythema gave essentially the same result. In contrast, where-
as the sunscreen was immunoprotective, its IPF was 4.9 (CI:
2.3^10.6), less than 50% of the sunscreen’s ability to prevent sun-
burn.This di¡erence in protection was statistically signi¢cant, the
ratio of IPF/Ery-PFg being 0.36 (95% CI: 0.12^0.81), p ¼ 0.03.
We believe that the most likely reason for the large discrepancy
between SPF (and the other two measures of erythema protec-
tion) and IPF is that UVA is relatively more immunosuppressive
than it is erythemogenic.This would mean that the action spectra
for erythema and immunosuppression are di¡erent and that the
major chromophores for these end-points are di¡erent.
There are relatively few data on the role of UVA in immuno-
suppression in humans, especially in terms of dose^response and
spectral dependency. A single exposure of 4 MED UVA-II was
highly e¡ective at suppressing the induction of CHS (LeVee
et al, 1997) but this was not seen with 3 MED UVA-1 (Skov
et al, 1997). Some workers have studied the e¡ects of UVA on
the elicitation rather than the induction phase of CHS. A single
low dose of UVA suppressed this response as did low-dose expo-
sures over 1^3 d but continued exposure (4 d^4 wk) did not
(Damian et al, 1999). Chronic exposure, however, suppressed the
elicitation of CHS (Moyal et al, 1997). In both these studies
(Moyal et al, 1997; Damian et al, 1999) broadband UVB þ UVA
sunscreens were more immunoprotective than UVB sunscreens.
Our data supports these chronic studies and implies that the
UVA component of sunlight is immunosuppressive.
We have reached our conclusions about an immunosuppressive
e¡ect of UVA by indirect means and so must consider other pos-
sible explanations for our results. Commercial sunscreens are
complex formulations not only containing the active sunscreen
¢lters but also unspeci¢ed perfumes, stabilizers, and preservatives.
The sunscreen we used contained vitamins A and E as anti-oxi-
dants, in unspeci¢ed concentrations. Topical anti-oxidants have
been reported to a¡ord low-level protection against UVR-in-
duced immunosuppression (Steenvoorden and Beijersbergen van
Henegouwen, 1999) and erythema (Montenegro et al, 1995), but
the relative e¡ectiveness of anti-oxidants in inhibiting these two
end-points has not been determined.
In this study, the sunscreen did not modify CHS responses in
unirradiated volunteers or induce irritation in unirradiated volun-
teers or volunteers exposed to 10 MED but it was not possible to
rule out completely a confounding e¡ect of a sunscreen constitu-
ent after SSR exposure.We have, however, reported that similar
IPF were obtained when octyl methoxycinnamate (the main
active ingredient of the current study) was applied directly
to mouse skin or to a substrate placed above the irradiation
cages, con¢rming that this ¢lter works by attenuation and do
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not interact with the skin to induce immunosuppression (Walker
and Young, 1997).
At present, there are no guidelines for the assessment of UVA
protection. Various in vivo and in vitro tests have been developed
but there is no consensus, within the pharmaceutical industry, as
to which one is the best to use. In the U.K., a sunscreen star rating
system (0^4 stars) has been uno⁄cially adopted by one of
the larger pharmaceutical companies (Boots the Chemist Ltd,
Nottingham, U.K.), which is an in vitro spectral assay based on
the Di¡ey method (Di¡ey and Robson, 1989) used in this study.
This is a measure of the ratio of UVA to UVB protection, for a
given SPF, with four stars being indicative of a ratio of 1:1. The
sunscreen we used had a star rating of 2. Our data suggest that
improved immunoprotection relative to SPF may be achieved
using sunscreens with high levels of UVA protection. It is impor-
tant to note that with the exception of erythema and epidermal
DNA damage (Young et al, 1998) we lack direct human data for
the wavelength dependency UVR e¡ects. It therefore appears
prudent to recommend use of sunscreens that attenuate all wave-
lengths equally, as even small di¡erences in wavelength depen-
dency could have large biologic e¡ects.
In conclusion, our data support the use of sunscreens as a
means of protecting against immunosuppression but indicate that
the level of immunoprotection o¡ered by a sunscreen cannot ne-
cessarily be predicted from its SPF. The most likely explanation
for this is that the action spectra for erythema and immunosup-
pression are di¡erent, with UVA being relatively more immuno-
suppressive that erythemogenic.We recommend that more direct
human studies are performed to con¢rm this. In addition, our
data con¢rm our previous ¢ndings that single, suberythemal ex-
posures of solar UVR, are highly immunosuppressive and im-
munosuppression is UVR dose dependent (Kelly et al, 2000).We
therefore recommend that sunscreens should not be used to pro-
long duration of sun exposure and that high SPF sunscreens that
o¡er broad-spectrum UVA protection (four-star rating) are used
to improve protection against immunosuppression.
We thank Professor Brian Di¡ey, Head of the Regional Medical Physics Department,
Newcastle uponTyne General Hospital, U.K., for providing the spectral transmission
data for the sunscreen and the UK Department of Health that funded the study (con-
tract number: 121/6379)
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